Furthermore, lncRNA sorafenib resistance in renal cell carcinoma associated (LNCSRLR) interacts with Hu antigen R to increase β-catenin expression, which subsequently activates the Wnt/β-catenin signaling pathway to promote cell proliferation. This evidence concerns the gene ELAVL1 and hereditary clear cell renal cell carcinoma.